Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy

Journal of Immunology

Volumn 174, Issue 9, 2005, Pages 5766-5773

  Gough, Michael ^a,b   Crittenden, Marka ^a   Thanarajasingam, Uma ^a   Sanchez Perez, Luis ^a   Thompson, Jill ^a   Jevremovic, Dragan ^a   Vile, Richard ^a  

^a MAYO CLINIC   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; CHEMOKINE; GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; VIRAL GENE THERAPY;

EID: 17844391297     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.9.5766     Document Type: Article

References (49)

1. Limmer, A., T. Sacher, J. Alferink, M. Kretschmar, G. Schonrich, T. Nichterlein, B. Arnold, and G. J. Hammerling. 1998. Failure to induce organ-specific autoimmunity by breaking of tolerance: Importance of the microenvironment. Eur. J. Immunol. 28:2395.
2. Hermans, I. F., A. Daish, J. Yang, D. S. Ritchie, and F. Ronchese, 1998. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res. 58:3909.
3. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. Zinkernagel, and P. S. Ohashi. 1991. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645.
4. --T-cell effector function and migration following viral infection, J. Virol. 77:4004.
5. Sallusto, F., C. R. Mackay, and A. Lanzavecchia. 2000. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18:593.
6. + T cells increase during viral infection and migrate to sites of infection. Eur. J. Immunol. 30:1797.
7. + T cells to the lung during influenza pneumonia. J. Immunol. 167:6983.
8. Garbi, N., B. Arnold, S. Gordon, G. J. Hammerling, and R. Ganss. 2004. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172:5861.
9. Fisher, B., B. S. Packard, E. J. Read, J. A. Carrasquillo, C. S. Carter, S. L. Topalian, J. C. Yang, P. Yolles, S. M. Larson, and S. A. Rosenberg. 1989. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7:250.
10. Pockaj, B. A., R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang. 1994. Localization of 111-indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer 73:1731.
11. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159.
12. Reinhardt, R. L., D. C. Bullard, C. T. Weaver, and M. K. Jenkins, 2003. Preferential accumulation of antigen-specific effector CD4 T cells at an antigen injection site involves CD62E-dependent migration but not local proliferation. J. Exp. Med. 197:751.
13. Mukai, S., J. Kjaergaard, S. Shu, and G. E. Plautz. 1999. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 59:5245.
14. Crittenden, M., M. Gough, K. Harrington, K. Olivier, J. Thompson, and R. G. Vile. 2003. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 63:5505.
15. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.
16. Buchanan, K. L., and J. W. Murphy. 1993. Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect. Immun. 61:2854.
17. Ahmed, A., D. Jevremovic, K. Suzuki, T. Kottke, J. Thompson, S. Emery, K. Harrington, A. Bateman, and R. Vile. 2003. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Ther. 10:1663.
18. Kim, C. H., K. Nagata, and E. C. Butcher. 2003. Dendritic cells support sequential reprogramming of chemoattractant receptor profiles during naive to effector T cell differentiation. J. Immunol. 171:152.
19. Mukai, T., M. Iwasaki, P. Gao, M. Tomura, Y. Yashiro-Ohtani, S. Ono, M. Murai, K. Matsushima, M. Kurimoto, M. Kogo, et al. 2001. IL-12 plays a pivotal role in LFA-1-mediated T cell adhesiveness by up-regulation of CCR5 expression. J. Leukocyte Biol. 70:422.
20. Murphy, P. M., M. Baggiolini, I. F. Charo, C. A. Hebert, R. Horuk, K. Matsushima, L. H. Miller, J. J. Oppenheim, and C. A. Power. 2000. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:145.
21. Kobayashi, K., K. Kaneda, and T. Kasama. 2001. Immunopathogenesis of delayed-type hypersensitivity. Microsc. Res. Tech. 53:241.
22. Schrama, D., L. O. Pedersen, P. Keikavoussi, M. H. Andersen, P. Straten Pt, E. B. Brocker, E. Kampgen, and J. C. Becker. 2002. Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells. J. Invest. Dermatol. 119:1443.
23. Degen, W. G., T. Jansen, and V. E. Schijns. 2003. Vaccine adjuvant technology: from mechanistic concepts to practical applications. Expert Rev. Vaccines 2:327.
24. Guermonprez, P., J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20:621.
25. Trombetta, E. S., M. Ebersold, W. Garrett, M. Pypaert, and I. Mellman. 2003. Activation of lysosomal function during dendritic cell maturation. Science 299:1400.
26. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782.
27. Pierre, P., S. J. Turley, E. Gatti, M. Hull, J. Meltzer, A. Mirza, K. Inaba, R. M. Steinman, and I. Mellman. 1997. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787.
28. Gretz, J. E., A. O. Anderson, and S. Shaw. 1997. Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol. Rev. 156:11.
29. Mackay, C. R., W. Marston, and L. Dudler. 1992. Altered patterns of T cell migration through lymph nodes and skin following antigen challenge. Eur. J. Immunol. 22:2205.
30. Janatpour, M. J., S. Hudak, M. Sathe, J. D. Sedgwick, and L. M. McEvoy. 2001. Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J. Exp. Med. 194:1375.
31. von Andrian, U. H., and C. R. Mackay. 2000. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343:1020.
32. D'Amico, G., G. Bianchi, S. Bernasconi, L. Bersani, L. Piemonti, S. Sozzani, A. Mantovani, and P. Allavena. 1998. Adhesion, transendothelial migration, and reverse transmigration of in vitro cultured dendritic cells. Blood 92:207.
33. Cavanagh, L. L., and U. H. Von Andrian. 2002. Travellers in many guises: the origins and destinations of dendritic cells. Immunol. Cell Biol. 80:448.
34. Bargatze, R. F., and E. C. Butcher. 1993. Rapid G protein-regulated activation event involved in lymphocyte binding to high endothelial venules. J. Exp. Med. 178:367.
35. Warnock, R. A., S. Askari, E. C. Butcher, and U. H. von Andrian. 1998. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. J. Exp. Med. 187:205.
36. Mathew, A., B. D. Medoff, A. D. Carafone, and A. D. Luster. 2002. Cutting edge: Th2 cell trafficking into the allergic lung is dependent on chemoattractant receptor signaling. J. Immunol. 169:651.
37. + T cells and intratumoral lymphotactin transgene expression. Cancer Res. 62:2043.
38. Huang, H., Y. Liu, and J. Xiang. 2002. Synergistic effect of adoptive T-cell therapy and intratumoral interferon γ-inducible protein-10 transgene expression in treatment of established tumors. Cell Immunol. 217:12.
39. Dorner, B. G., A. Scheffold, M. S. Rolph, M. B. Huser, S. H. Kaufmann, A. Radbruch, I.E. Flesch, and R. A. Kroczek. 2002. MIP-1α, MIP-1β, RANTES, and ATAC/lymphotactin function together with IFN-γ as type 1 cytokines. Proc. Natl. Acad. Sci. USA 99:6181.
40. + T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J. Clin. Invest. 104:49.
41. + T cells from a memory to memory/effector phenotype. J. Immunol. 168:5538.
42. + T cells. Eur. J. Immunol. 31:2411.
43. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immuno-regulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
44. Uekusa, Y., W. G. Yu, T. Mukai, P. Gao, N. Yamaguchi, M. Murai, K. Matsushima, S. Obika, T. Imanishi, Y. Higashibata, et al. 2002. A pivotal role for CC chemokine receptor 5 in T-cell migration, to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res. 62:3751.
45. van Deventer, H. W., J. S. Serody, K. P. McKinnon, C. Clements, W. J. Brickey, and J. P. Ting. 2002. Transfection of macrophage inflammatory protein 1 alpha into B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors. J. Immunol. 169:1634.
46. Prasad, S. A., C. C. Norbury, W. Chen, J. R. Bennink, and J. W. Yewdell. 2001. Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J. Immunol. 166:4809.
47. Kafri, T., D. Morgan, T. Krahl, N. Sarvetnick, L. Sherman, and I. Verma. 1998. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc. Natl. Acad. Sci. USA 95:11377.
48. Butterfield, L. H., A. Ribas, V. B. Dissette, S. N. Amamani, H. T. Vu, D. Oseguera, H. J. Wang, R. M. Elashoff, W. H. McBride, B. Mukherji, et al. 2003. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9:998.
49. Kershaw, M. H., G. Wang, J. A. Westwood, R. K. Pachynski, H. L. Tiffany, F. M. Marincola, E. Wang, H. A. Young, P. M. Murphy, and P. Hwu. 2002. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13:1971.